<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>2448-9190</journal-id>
<journal-title><![CDATA[Revista alergia México]]></journal-title>
<abbrev-journal-title><![CDATA[Rev. alerg. Méx.]]></abbrev-journal-title>
<issn>2448-9190</issn>
<publisher>
<publisher-name><![CDATA[Colegio Mexicano de Inmunología Clínica y Alergia A.C.]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S2448-91902020000200096</article-id>
<article-id pub-id-type="doi">10.29262/ram.v67i2.670</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Frecuencia de reacciones adversas a sulfametoxazol con trimetoprima y factores de riesgo en pacientes con VIH]]></article-title>
<article-title xml:lang="en"><![CDATA[The frequency of adverse reactions to sulfamethoxazole with trimethoprim and risk factors in HIV patients]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Martínez-Martínez]]></surname>
<given-names><![CDATA[María del Carmen]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Hernández-Morales]]></surname>
<given-names><![CDATA[María del Rocío]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Mancilla-Hernández]]></surname>
<given-names><![CDATA[Eleazar]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Benemérita Universidad Autónoma de Puebla Facultad de Medicina ]]></institution>
<addr-line><![CDATA[ Puebla]]></addr-line>
<country>Mexico</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,Secretaría de Salud Hospital General de Puebla ]]></institution>
<addr-line><![CDATA[ Puebla]]></addr-line>
<country>Mexico</country>
</aff>
<aff id="Af3">
<institution><![CDATA[,Centro de Investigación en el Área de la Salud  ]]></institution>
<addr-line><![CDATA[ Puebla]]></addr-line>
<country>Mexica</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>06</month>
<year>2020</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>06</month>
<year>2020</year>
</pub-date>
<volume>67</volume>
<numero>2</numero>
<fpage>96</fpage>
<lpage>101</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_arttext&amp;pid=S2448-91902020000200096&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_abstract&amp;pid=S2448-91902020000200096&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_pdf&amp;pid=S2448-91902020000200096&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen  Antecedentes:  Trimetoprima-sulfametoxazol (TMP-SMZ) es el antimicrobiano de elección y de uso prolongado en la prevención y tratamiento de infecciones por gérmenes oportunistas en los pacientes con síndrome de inmunodeficiencia adquirida (sida), en quienes la frecuencia de reacciones adversas a medicamentos es de 30 a 50 %.  Objetivo:  Determinar las reacciones adversas a TMP-SMZ y sus factores de riesgo en pacientes con sida. Métodos: Se incluyeron pacientes mayores de 18 años con diagnóstico confirmado de infección por VIH y que presentaron reacción adversa a fármacos, de enero de 2018 a mayo de 2019. Se revisaron 319 expedientes.  Resultados:  Se reportó 13.16 % de reacciones adversas; de 42 pacientes con reacciones adversas a medicamentos, 23 fueron a TMP-SMZ (54.76 %). El rash representó 56.5 % de las reacciones adversas, el angioedema 21.73 % y la urticaria 17.39 %. Los factores de riesgo fueron la comorbilidad infecciosa (RM = 2.6) y la cuenta de CD4 &lt; 100 (RM = 6.9), sin significación estadística; la dosis de TMP-SMZ fue un factor de riesgo (RM = 12.7), con p = 0.017.  Conclusiones:  El TMP-SMZ en los pacientes con sida ocasionó 54 % de las reacciones adversas a medicamentos y la dosis fue un factor de riesgo.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstract  Background:  Trimethoprim-sulfamethoxazole (TMP-SMZ) is the long-term use antimicrobial of choice in the prevention and treatment of opportunistic germs in patients with acquired immunodeficiency syndrome (AIDS) in whom the frequency of ADR (adverse drug reactions) is of 30% to 50 %.  Objective:  To determine the adverse reactions to TMP-SMZ and their risk factors in AIDS patients.  Methods:  The patients included in the study were older than 18 years of age, admitted from January 2018 to May 2019 with a confirmed diagnosis of HIV, and had had adverse drug reactions; 319 files were reviewed.  Results:  A frequency of 13.16 % in adverse reactions was reported; out of 42 patients with ADR, 23 had had ADR to TMP-SMZ (54.76 %). The highest rate of adverse reactions was represented by a rash, with 56.5 %, followed by angioedema, with 21.73 %, and nettle rash, with 17.39 %. The risk factors were: infectious comorbidity (OR = 2.6) and CD4 count &lt; 100 (OR = 6.9), without statistical significance. The dose of TMP/SMZ was a risk factor (OR = 12.7) with p = 0.017.  Conclusions:  TMP-SMZ used in AIDS patients reached 54 % of the adverse drug reactions, and the dose of this medication was a risk factor.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[Reacciones adversas a los medicamentos]]></kwd>
<kwd lng="es"><![CDATA[Trimetroprim con sulfametoxazol]]></kwd>
<kwd lng="es"><![CDATA[Síndrome de inmunodeficiencia adquirida]]></kwd>
<kwd lng="en"><![CDATA[Adverse drug reactions]]></kwd>
<kwd lng="en"><![CDATA[Trimethoprim-sulfamethoxazole]]></kwd>
<kwd lng="en"><![CDATA[Acquired immunodeficiency syndrome]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Esteban]]></surname>
<given-names><![CDATA[CS.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[VIH: infección aguda, pesquisa y manejo]]></article-title>
<source><![CDATA[Rev Med Clin Condes.]]></source>
<year>2014</year>
<volume>25</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>419-24</page-range></nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Carrillo-Maravilla]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Villegas-Jiménez]]></surname>
<given-names><![CDATA[A.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[El descubrimiento del VIH en los albores de la epidemia del sida]]></article-title>
<source><![CDATA[Rev Invest Clin.]]></source>
<year>2004</year>
<volume>56</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>130-3</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="">
<collab>Organización Mundial de la Salud</collab>
<source><![CDATA[Suiza: Estrategia mundial del sector de la salud contra el VIH, 2016-2021]]></source>
<year>2016</year>
</nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="">
<collab>Secretaría de Salud</collab>
<collab>Centro Nacional para la Prevención y el Control del VIH y sida</collab>
<collab>Dirección General de Epidemología</collab>
<source><![CDATA[Vigilancia epidemiológica de casos de VIH/sida en México. México: Registro nacional de casos de sida]]></source>
<year>2019</year>
</nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Woodman]]></surname>
<given-names><![CDATA[Z]]></given-names>
</name>
<name>
<surname><![CDATA[Williamson]]></surname>
<given-names><![CDATA[C.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[HIV molecular epidemiology: transmission and adaptation to human populations]]></article-title>
<source><![CDATA[Curr Opin HIV AIDS]]></source>
<year>2009</year>
<volume>4</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>247-52</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Juno]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
<name>
<surname><![CDATA[Bockel]]></surname>
<given-names><![CDATA[DV]]></given-names>
</name>
<name>
<surname><![CDATA[Kent]]></surname>
<given-names><![CDATA[SJ]]></given-names>
</name>
<name>
<surname><![CDATA[Kelleher]]></surname>
<given-names><![CDATA[AD]]></given-names>
</name>
<name>
<surname><![CDATA[Zaunders]]></surname>
<given-names><![CDATA[JJ]]></given-names>
</name>
<name>
<surname><![CDATA[Munier]]></surname>
<given-names><![CDATA[ML.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Cytotoxic CD4T cells-Friend or Foe during viral infection?]]></article-title>
<source><![CDATA[Front Immunol.]]></source>
<year>2017</year>
<volume>8</volume>
<numero>19</numero>
<issue>19</issue>
</nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sánchez-Martínez]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Perdomo-Celis]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Acevedo-Sáenz]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Rugeles]]></surname>
<given-names><![CDATA[MT]]></given-names>
</name>
<name>
<surname><![CDATA[Velilla]]></surname>
<given-names><![CDATA[PA.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Cytotoxic CD4 T cells during HIV infection: targets or weapons]]></article-title>
<source><![CDATA[J Clin Virol.]]></source>
<year>2019</year>
<volume>119</volume>
<page-range>17-23</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Terrazas-Estrada]]></surname>
<given-names><![CDATA[JJ.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[A 30 años de la infección por el virus de la inmunodeficiencia humana]]></article-title>
<source><![CDATA[Rev Alerg Mex.]]></source>
<year>2011</year>
<volume>58</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>205-12</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Chevalier]]></surname>
<given-names><![CDATA[MF]]></given-names>
</name>
<name>
<surname><![CDATA[Didier]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Girard]]></surname>
<given-names><![CDATA[PM]]></given-names>
</name>
<name>
<surname><![CDATA[Manea]]></surname>
<given-names><![CDATA[ME]]></given-names>
</name>
<name>
<surname><![CDATA[Campa]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Barré-Sinoussi]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[CD4 T-cell responses in primary HIV infection: interrelationship with immune activation and virus burden]]></article-title>
<source><![CDATA[Front Immunol.]]></source>
<year>2016</year>
<volume>7</volume>
<page-range>1-7</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Paul]]></surname>
<given-names><![CDATA[ME]]></given-names>
</name>
<name>
<surname><![CDATA[Shearer]]></surname>
<given-names><![CDATA[WT]]></given-names>
</name>
<name>
<surname><![CDATA[Kozinetz]]></surname>
<given-names><![CDATA[CA]]></given-names>
</name>
<name>
<surname><![CDATA[Lewis]]></surname>
<given-names><![CDATA[DE.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Comparison of CD8(+)T-cell subsets in HIV-infected rapid progressor children versus non-rapid progressor children]]></article-title>
<source><![CDATA[J Allergy Clin Immunol.]]></source>
<year>2001</year>
<volume>108</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>258-64</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sisay]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Bote]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Edessa]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Mengisto]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Amare]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Gashaw]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Appropriateness of cotrimoxazole prophylactic therapy among HIV/AIDS patients in public hospitals in Eastein Ethiopia: a retrospective evaluation of clinical practice]]></article-title>
<source><![CDATA[Front Pharmacol.]]></source>
<year>2018</year>
<volume>9</volume>
<numero>727</numero>
<issue>727</issue>
</nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Moreno]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Moreno]]></surname>
<given-names><![CDATA[A.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Alergia a los fármacos en el paciente con infección por el VIH. Alergia a otros agentes antiinfecciosos poco habituales: antirretrovirales, sulfamidas, antituberculosos y otros.]]></article-title>
<source><![CDATA[Tratado de Alergología]]></source>
<year>2019</year>
<page-range>1437-60</page-range><publisher-loc><![CDATA[España ]]></publisher-loc>
<publisher-name><![CDATA[Ergon]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Carr]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Swanson]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Penny]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Cooper]]></surname>
<given-names><![CDATA[DA.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Clinical and laboratory markers of hypersensitivity to trimethoprim-sulfamethoxazole in patients with Pneumocystis carinii pneumonia and AIDS]]></article-title>
<source><![CDATA[J Infect Dis.]]></source>
<year>1993</year>
<volume>167</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>180-5</page-range></nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Veenstra]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Veugelers]]></surname>
<given-names><![CDATA[PJ]]></given-names>
</name>
<name>
<surname><![CDATA[Keet]]></surname>
<given-names><![CDATA[IP]]></given-names>
</name>
<name>
<surname><![CDATA[van der Ven]]></surname>
<given-names><![CDATA[AJ]]></given-names>
</name>
<name>
<surname><![CDATA[Miedema]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Lange]]></surname>
<given-names><![CDATA[JM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Rapid disease progression in human immunodeficiency virus type 1-Infected individuals with adverse reactions to trimetoprim-sulfamethoxazole prophylaxis]]></article-title>
<source><![CDATA[Clin Infect Dis.]]></source>
<year>1997</year>
<volume>24</volume>
<page-range>936-41</page-range></nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Belchi-Hernández]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Espinosa-Parra]]></surname>
<given-names><![CDATA[FJ.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Management of adverse reactions to prophylactic trimethoprim-sulfamethoxazole in patients with human immunodeficiency virus infection]]></article-title>
<source><![CDATA[Ann Allergy Asthma Immunol.]]></source>
<year>1996</year>
<volume>76</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>355-8</page-range></nlm-citation>
</ref>
<ref id="B16">
<label>16</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Shafer]]></surname>
<given-names><![CDATA[RW]]></given-names>
</name>
<name>
<surname><![CDATA[Seitzman]]></surname>
<given-names><![CDATA[PA]]></given-names>
</name>
<name>
<surname><![CDATA[Tapper]]></surname>
<given-names><![CDATA[ML.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Successful prophylaxis of Pneumocystis carinii pneumonia with trimethoprim-sulfamethoxazole in AIDS patients with previous allergic reactions]]></article-title>
<source><![CDATA[J Acquir Immune Defic Syndr.]]></source>
<year>1989</year>
<volume>2</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>389-93</page-range></nlm-citation>
</ref>
<ref id="B17">
<label>17</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rabaud]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Charreau]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Izard]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Raffi]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Meiffredy]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Lepor]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Adverse reactions to cotrimoxazole in HIV-infected patients: predictive factors and subsequent HIV disease progression]]></article-title>
<source><![CDATA[Scand J Infect Dis.]]></source>
<year>2001</year>
<volume>33</volume>
<numero>10</numero>
<issue>10</issue>
<page-range>759-64</page-range></nlm-citation>
</ref>
<ref id="B18">
<label>18</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Chang]]></surname>
<given-names><![CDATA[HM]]></given-names>
</name>
<name>
<surname><![CDATA[Tsai]]></surname>
<given-names><![CDATA[HC]]></given-names>
</name>
<name>
<surname><![CDATA[Lee]]></surname>
<given-names><![CDATA[SSJ]]></given-names>
</name>
<name>
<surname><![CDATA[Kunin]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Lin]]></surname>
<given-names><![CDATA[PC]]></given-names>
</name>
<name>
<surname><![CDATA[Wan]]></surname>
<given-names><![CDATA[SR]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[High daily doses of trimethoprim/sulfamethoxazole are an independent risk factor for adverse reactions in patients with pneumocystis pneumonia and AIDS]]></article-title>
<source><![CDATA[J Clin Med Assoc.]]></source>
<year>2016</year>
<volume>79</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>314-9</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
